TWST
Twist Bioscience Corporation
Price Chart
Latest Quote
$82.87
-2.08 (-2.45%)
Current Price
| Previous Close | $84.95 |
| Open | $85.42 |
| Day High | $88.46 |
| Day Low | $81.62 |
| Volume | 1,775,220 |
Stock Information
| Shares Outstanding | 62.27M |
| Total Debt | $110.84M |
| Cash Equivalents | $171.67M |
| Revenue | $409.48M |
| Net Income | $-81.28M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $5.16B |
| EPS (TTM) | $-1.32 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.23B |
| Sales | $409.48M |
| Income | $-81.28M |
| Book/sh | $7.32 |
| Cash/sh | $2.76 |
| Employees | 979 |
Financial Ratios
| Quick Ratio | 2.04 |
| Current Ratio | 2.70 |
| Debt/Eq | 24.36 |
Returns & Margins
| ROA | -12.93% |
| ROE | -18.16% |
| Gross Margin | 52.07% |
| Operating Margin | -34.92% |
| Profit Margin | -19.85% |
Ownership
| Insider Ownership | 1.26% |
| Institutional Ownership | 123.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -85.43 |
| P/S | 12.60 |
| P/B | 11.32 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $71.10 |
Technical Indicators
| SMA20 | $69.91 |
| SMA50 | $61.73 |
| SMA200 | $42.88 |
| RSI | 69.05 |
| ATR | 5.3657 |
| Shares Float | 55.42M |
| Short Float | 30.69% |
| Short Ratio | 9.29 |
| Volatility | 2.21 |
| Rel Volume | 0.96 |
Performance History
| Week | +22.28% |
| Month | +66.44% |
| Quarter | +86.39% |
| 6 Months | +166.72% |
| YTD | +155.85% |
| Year | +136.50% |
| 3 Years | +350.87% |
| 5 Years | -25.79% |
| 10 Years | +491.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $82.87 | 1,823,600 |
| 2026-06-16 | $84.95 | 2,482,200 |
| 2026-06-15 | $80.79 | 2,642,800 |
| 2026-06-12 | $76.17 | 2,612,100 |
| 2026-06-11 | $74.05 | 2,742,800 |
| 2026-06-10 | $67.77 | 1,145,200 |
| 2026-06-09 | $70.06 | 1,797,000 |
| 2026-06-08 | $70.04 | 1,395,100 |
| 2026-06-05 | $69.22 | 2,474,200 |
| 2026-06-04 | $73.93 | 2,041,500 |
| 2026-06-03 | $72.33 | 1,431,500 |
| 2026-06-02 | $70.15 | 1,087,700 |
| 2026-06-01 | $67.86 | 1,294,900 |
| 2026-05-29 | $66.87 | 2,132,700 |
| 2026-05-28 | $69.03 | 2,263,700 |
| 2026-05-27 | $64.17 | 1,305,800 |
| 2026-05-26 | $64.87 | 1,600,000 |
| 2026-05-22 | $60.57 | 1,617,900 |
| 2026-05-21 | $58.84 | 2,027,300 |
| 2026-05-20 | $53.66 | 2,111,700 |
| 2026-05-19 | $49.50 | 870,400 |
| 2026-05-18 | $49.79 | 1,144,500 |
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
đ° Latest News
Twist Bioscience (TWST) Stock Could Be 25.5% Overvalued After Its Recent Rally
Simply Wall St. âĸ 2026-06-16T11:11:04Z
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
Insider Monkey âĸ 2026-06-16T02:34:59Z
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
GuruFocus.com âĸ 2026-06-15T18:48:08ZDatadog upgraded, Accenture downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-15T13:42:48Z
Here Are Mondayâs Best Wall Street Analyst Research Calls: Accenture, Caesars Entertainment, Datadog, DuPont, EPAM Systems, Ferrari, Paychex, Rocket Lab, TeraWulf, and More
24/7 Wall St. âĸ 2026-06-15T12:03:56Z
Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts
Insider Monkey âĸ 2026-06-15T05:09:04Z
Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers
Insider Monkey âĸ 2026-06-15T05:03:59Z
Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.
Motley Fool âĸ 2026-06-12T19:56:45Z
Cathie Wood Liquidates $279 Million Worth Of Stock This Week
Investor's Business Daily âĸ 2026-06-12T14:57:17Z
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Zacks âĸ 2026-06-12T12:25:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $185,570,000 | $179,625,000 | $155,380,000 | $119,330,000 |
| Cost Of Revenue | $185,570,000 | $179,625,000 | $155,380,000 | $119,330,000 |
| Total Revenue | $376,572,000 | $312,974,000 | $245,109,000 | $203,565,000 |
| Operating Revenue | $376,572,000 | $312,974,000 | $245,109,000 | $203,565,000 |
| Expenses | ||||
| Total Expenses | $512,831,000 | $488,875,000 | $452,012,000 | $452,586,000 |
| Other Income Expense | $47,944,000 | $-47,609,000 | $-10,928,000 | $17,765,000 |
| Other Non Operating Income Expenses | $-903,000 | $-2,679,000 | $-672,000 | $-1,087,000 |
| Net Non Operating Interest Income Expense | $11,364,000 | $15,344,000 | $14,365,000 | $2,982,000 |
| Operating Expense | $327,261,000 | $309,250,000 | $296,632,000 | $333,256,000 |
| Interest Expense | - | $29,000 | $5,000 | $80,000 |
| Interest Expense Non Operating | - | $29,000 | $5,000 | $80,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Net Interest Income | $11,364,000 | $15,344,000 | $14,365,000 | $2,982,000 |
| Interest Income | $11,364,000 | $15,344,000 | $14,365,000 | $3,062,000 |
| Normalized Income | $-116,259,130 | $-163,796,000 | $-196,515,760 | $-235,772,400 |
| Net Income From Continuing And Discontinued Operation | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Total Operating Income As Reported | $-136,259,000 | $-220,831,000 | $-217,159,000 | $-234,776,000 |
| Net Income Common Stockholders | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Net Income | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Net Income Including Noncontrolling Interests | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Net Income Continuous Operations | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Pretax Income | $-76,951,000 | $-208,166,000 | $-203,466,000 | $-228,274,000 |
| Special Income Charges | $48,847,000 | $-44,930,000 | $-10,256,000 | $18,852,000 |
| Interest Income Non Operating | $11,364,000 | $15,344,000 | $14,365,000 | $3,062,000 |
| Operating Income | $-136,259,000 | $-175,901,000 | $-206,903,000 | $-249,021,000 |
| Gross Profit | $191,002,000 | $133,349,000 | $89,729,000 | $84,235,000 |
| Per Share | ||||
| Diluted EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 |
| Basic EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 |
| Other | ||||
| Tax Effect Of Unusual Items | $10,257,870 | $0 | $-2,153,760 | $942,600 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-160,253,000 | $-99,539,000 | $-167,337,000 | $-230,532,000 |
| Total Unusual Items | $48,847,000 | $-44,930,000 | $-10,256,000 | $18,852,000 |
| Total Unusual Items Excluding Goodwill | $48,847,000 | $-44,930,000 | $-10,256,000 | $18,852,000 |
| Reconciled Depreciation | $24,853,000 | $31,432,000 | $29,310,000 | $16,514,000 |
| EBITDA (Bullshit earnings) | $-111,406,000 | $-144,469,000 | $-177,593,000 | $-211,680,000 |
| EBIT | $-136,259,000 | $-175,901,000 | $-206,903,000 | $-228,194,000 |
| Diluted Average Shares | $59,808,000 | $58,016,000 | $56,885,000 | $53,885,000 |
| Basic Average Shares | $59,808,000 | $58,016,000 | $56,885,000 | $53,885,000 |
| Diluted NI Availto Com Stockholders | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Tax Provision | $719,000 | $560,000 | $1,152,000 | $-10,411,000 |
| Gain On Sale Of Business | $48,847,000 | $0 | $0 | $4,607,000 |
| Impairment Of Capital Assets | $0 | $44,930,000 | $6,785,000 | $0 |
| Restructuring And Mergern Acquisition | $0 | $0 | $3,471,000 | $-14,245,000 |
| Research And Development | $80,285,000 | $90,852,000 | $106,894,000 | $120,307,000 |
| Selling General And Administration | $246,976,000 | $218,398,000 | $189,738,000 | $212,949,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $377,338,000 | $372,400,000 | $483,138,000 | $643,836,000 |
| Total Assets | $641,861,000 | $614,323,000 | $776,403,000 | $961,378,000 |
| Total Non Current Assets | $308,895,000 | $267,547,000 | $352,147,000 | $364,896,000 |
| Other Non Current Assets | $7,278,000 | $4,384,000 | $8,492,000 | $4,957,000 |
| Investmentin Financial Assets | $54,337,000 | $1,525,000 | - | - |
| Goodwill And Other Intangible Assets | $95,620,000 | $100,289,000 | $140,294,000 | $145,549,000 |
| Other Intangible Assets | $13,425,000 | $14,478,000 | $54,483,000 | $59,738,000 |
| Current Assets | $332,966,000 | $346,776,000 | $424,256,000 | $596,483,000 |
| Other Current Assets | $15,204,000 | $11,396,000 | $11,716,000 | $11,914,000 |
| Inventory | $28,309,000 | $24,078,000 | $32,063,000 | $39,307,000 |
| Receivables | $57,019,000 | $34,903,000 | $44,064,000 | $40,294,000 |
| Accounts Receivable | $57,019,000 | $34,903,000 | $44,064,000 | $40,294,000 |
| Allowance For Doubtful Accounts Receivable | $-600,000 | $-700,000 | $-200,000 | $-200,000 |
| Gross Accounts Receivable | $57,619,000 | $35,603,000 | $44,264,000 | $40,494,000 |
| Cash Cash Equivalents And Short Term Investments | $232,434,000 | $276,399,000 | $336,413,000 | $504,968,000 |
| Cash And Cash Equivalents | $183,049,000 | $226,316,000 | $286,470,000 | $378,687,000 |
| Cash Equivalents | $150,372,000 | $199,858,000 | $245,654,000 | - |
| Cash Financial | $32,677,000 | $26,458,000 | $40,816,000 | - |
| Non Current Note Receivables | - | - | - | $0 |
| Prepaid Assets | - | - | - | $11,914,000 |
| Receivables Adjustments Allowances | - | - | - | $-234,000 |
| Other Receivables | - | - | - | $4,822,000 |
| Debt | ||||
| Total Debt | $75,572,000 | $85,026,000 | $94,069,000 | $94,912,000 |
| Long Term Debt And Capital Lease Obligation | $61,750,000 | $70,221,000 | $79,173,000 | $81,270,000 |
| Current Debt And Capital Lease Obligation | $13,822,000 | $14,805,000 | $14,896,000 | $13,642,000 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $168,903,000 | $141,634,000 | $152,971,000 | $171,993,000 |
| Total Non Current Liabilities Net Minority Interest | $77,497,000 | $70,628,000 | $79,648,000 | $81,330,000 |
| Other Non Current Liabilities | $747,000 | $407,000 | $475,000 | $60,000 |
| Non Current Deferred Liabilities | $15,000,000 | $0 | - | - |
| Current Liabilities | $91,406,000 | $71,006,000 | $73,323,000 | $90,663,000 |
| Other Current Liabilities | $722,000 | $961,000 | $430,000 | $12,600,000 |
| Current Deferred Liabilities | $6,884,000 | $2,131,000 | $2,999,000 | $3,476,000 |
| Payables And Accrued Expenses | $38,690,000 | $19,459,000 | $29,180,000 | $33,922,000 |
| Payables | $15,637,000 | $4,355,000 | $18,426,000 | $23,753,000 |
| Total Tax Payable | $4,543,000 | $2,725,000 | $4,374,000 | $3,661,000 |
| Accounts Payable | $11,094,000 | $1,630,000 | $14,052,000 | $20,092,000 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $472,958,000 | $472,689,000 | $623,432,000 | $789,385,000 |
| Total Equity Gross Minority Interest | $472,958,000 | $472,689,000 | $623,432,000 | $789,385,000 |
| Stockholders Equity | $472,958,000 | $472,689,000 | $623,432,000 | $789,385,000 |
| Gains Losses Not Affecting Retained Earnings | $-627,000 | $-522,000 | $-756,000 | $-1,843,000 |
| Other Equity Adjustments | $-627,000 | $-522,000 | $-756,000 | $-1,843,000 |
| Retained Earnings | $-1,319,578,000 | $-1,241,908,000 | $-1,033,034,000 | $-828,416,000 |
| Other | ||||
| Ordinary Shares Number | $60,631,000 | $58,877,000 | $57,557,000 | $56,523,000 |
| Share Issued | $60,631,000 | $58,877,000 | $57,557,000 | $56,523,000 |
| Tangible Book Value | $377,338,000 | $372,400,000 | $483,138,000 | $643,836,000 |
| Invested Capital | $472,958,000 | $472,689,000 | $623,432,000 | $789,385,000 |
| Working Capital | $241,560,000 | $275,770,000 | $350,933,000 | $505,820,000 |
| Capital Lease Obligations | $75,572,000 | $85,026,000 | $94,069,000 | $94,912,000 |
| Total Capitalization | $472,958,000 | $472,689,000 | $623,432,000 | $789,385,000 |
| Additional Paid In Capital | $1,793,163,000 | $1,715,119,000 | $1,657,222,000 | $1,619,644,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $15,000,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $61,750,000 | $70,221,000 | $79,173,000 | $81,270,000 |
| Current Deferred Revenue | $6,884,000 | $2,131,000 | $2,999,000 | $3,476,000 |
| Current Capital Lease Obligation | $13,822,000 | $14,805,000 | $14,896,000 | $13,642,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $31,288,000 | $33,650,000 | $25,818,000 | $27,023,000 |
| Current Accrued Expenses | $23,053,000 | $15,104,000 | $10,754,000 | $10,169,000 |
| Investments And Advances | $54,337,000 | $1,525,000 | - | - |
| Available For Sale Securities | $54,337,000 | $1,525,000 | - | - |
| Goodwill | $82,195,000 | $85,811,000 | $85,811,000 | $85,811,000 |
| Net PPE | $151,660,000 | $161,349,000 | $203,361,000 | $214,390,000 |
| Accumulated Depreciation | $-94,994,000 | $-75,643,000 | $-50,656,000 | $-31,777,000 |
| Gross PPE | $246,654,000 | $236,992,000 | $254,017,000 | $246,167,000 |
| Leases | $58,277,000 | $57,448,000 | $57,271,000 | $14,371,000 |
| Construction In Progress | $20,116,000 | $4,688,000 | $8,528,000 | $87,723,000 |
| Other Properties | $150,960,000 | $158,357,000 | $176,039,000 | $137,233,000 |
| Machinery Furniture Equipment | $17,301,000 | $16,499,000 | $12,179,000 | $6,840,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,853,000 | $4,616,000 | $3,926,000 | $7,654,000 |
| Work In Process | $2,265,000 | $2,146,000 | $1,113,000 | $2,866,000 |
| Raw Materials | $20,191,000 | $17,316,000 | $27,024,000 | $28,787,000 |
| Other Short Term Investments | $49,385,000 | $50,083,000 | $49,943,000 | $126,281,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-75,632,000 | $-69,170,000 | $-170,253,000 | $-226,242,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-47,628,000 | $-64,094,000 | $-142,474,000 | $-124,385,000 |
| Cash Flow From Continuing Operating Activities | $-47,628,000 | $-64,094,000 | $-142,474,000 | $-124,385,000 |
| Operating Gains Losses | $-48,847,000 | - | - | $-4,607,000 |
| Investing Activities | ||||
| Capital Expenditure | $-28,004,000 | $-5,076,000 | $-27,779,000 | $-101,857,000 |
| Investing Cash Flow | $-24,762,000 | $-3,071,000 | $50,612,000 | $-232,930,000 |
| Cash Flow From Continuing Investing Activities | $-24,762,000 | $-3,071,000 | $50,612,000 | $-232,930,000 |
| Net Other Investing Changes | - | - | - | $-5,755,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-16,000 | $-3,975,000 | $-4,405,000 | $-7,754,000 |
| Financing Cash Flow | $28,540,000 | $6,890,000 | $911,000 | $270,534,000 |
| Cash Flow From Continuing Financing Activities | $28,540,000 | $6,890,000 | $911,000 | $270,534,000 |
| Net Other Financing Charges | $15,000,000 | - | - | - |
| Net Common Stock Issuance | $-16,000 | $-3,975,000 | $-4,405,000 | $262,068,000 |
| Issuance Of Capital Stock | - | $0 | $0 | $269,822,000 |
| Common Stock Issuance | - | $0 | $0 | $269,822,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $683,000 | $344,000 | $420,000 | $246,000 |
| End Cash Position | $185,425,000 | $229,132,000 | $289,281,000 | $380,259,000 |
| Beginning Cash Position | $229,132,000 | $289,281,000 | $380,259,000 | $467,359,000 |
| Effect Of Exchange Rate Changes | $143,000 | $126,000 | $-27,000 | $-319,000 |
| Changes In Cash | $-43,850,000 | $-60,275,000 | $-90,951,000 | $-86,781,000 |
| Proceeds From Stock Option Exercised | $13,556,000 | $10,865,000 | $5,316,000 | $10,024,000 |
| Common Stock Payments | $-16,000 | $-3,975,000 | $-4,405,000 | $-7,754,000 |
| Net Investment Purchase And Sale | $742,000 | $2,005,000 | $78,391,000 | $-117,158,000 |
| Sale Of Investment | $50,135,000 | $53,910,000 | $154,736,000 | $100,481,000 |
| Purchase Of Investment | $-49,393,000 | $-51,905,000 | $-76,345,000 | $-217,639,000 |
| Net Business Purchase And Sale | $2,500,000 | $0 | $0 | $-13,915,000 |
| Sale Of Business | $2,500,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-28,004,000 | $-5,076,000 | $-27,779,000 | $-101,857,000 |
| Purchase Of PPE | $-28,004,000 | $-5,076,000 | $-27,779,000 | $-101,857,000 |
| Change In Working Capital | $-12,606,000 | $15,411,000 | $-1,009,000 | $-5,356,000 |
| Change In Other Current Liabilities | $6,612,000 | $-2,317,000 | $-108,000 | $-7,424,000 |
| Change In Other Current Assets | $-1,568,000 | $431,000 | $1,376,000 | $7,273,000 |
| Change In Payables And Accrued Expense | $12,678,000 | $485,000 | $-1,029,000 | $14,504,000 |
| Change In Accrued Expense | $3,346,000 | $12,290,000 | $1,479,000 | $7,121,000 |
| Change In Payable | $9,332,000 | $-11,805,000 | $-2,508,000 | $7,383,000 |
| Change In Account Payable | $9,332,000 | $-11,805,000 | $-2,508,000 | $7,383,000 |
| Change In Prepaid Assets | $-3,717,000 | $382,000 | $-4,166,000 | $-2,551,000 |
| Change In Inventory | $-4,229,000 | $7,986,000 | $7,238,000 | $-7,536,000 |
| Change In Receivables | $-22,382,000 | $8,444,000 | $-4,320,000 | $-9,622,000 |
| Changes In Account Receivables | $-22,382,000 | $8,444,000 | $-4,320,000 | $-9,622,000 |
| Other Non Cash Items | $2,183,000 | $1,934,000 | $-3,220,000 | $7,263,000 |
| Stock Based Compensation | $64,459,000 | $50,925,000 | $30,278,000 | $79,664,000 |
| Asset Impairment Charge | $0 | $44,930,000 | $6,785,000 | $0 |
| Depreciation Amortization Depletion | $24,853,000 | $31,432,000 | $29,310,000 | $16,514,000 |
| Depreciation And Amortization | $24,853,000 | $31,432,000 | $29,310,000 | $16,514,000 |
| Gain Loss On Sale Of Business | $-48,847,000 | $0 | $0 | $-4,607,000 |
| Net Income From Continuing Operations | $-77,670,000 | $-208,726,000 | $-204,618,000 | $-217,863,000 |
| Repayment Of Debt | - | $0 | $0 | $-1,558,000 |
| Interest Paid Supplemental Data | - | $0 | $0 | $9,000 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $-1,558,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $-1,558,000 |
| Long Term Debt Payments | - | $0 | $0 | $-1,558,000 |
| Purchase Of Business | - | $0 | $0 | $-13,915,000 |
| Change In Other Working Capital | - | - | - | $4,852,000 |
| Provisionand Write Offof Assets | - | - | - | $-11,000 |
| Amortization Of Securities | - | - | - | $1,315,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-17